ERBB2 and breast carcinoma: Although the relationship between EGFR/HER-2/ERK signaling and cisplatin resistance in breast cancer cells remains to be defined, the inhibition of the MAPK pathways sensitizes basal-like MDA-MB-468 cells to cisplatin treatment [34].